William Harbour, MD, director of Bascom Palmer’s Ocular Oncology Laboratory and mentor of Kaler, pointed out in the release that it has been known for decades that uveal melanomas become more aggressive by lulling the immune system to sleep so that it does not attack. Kaler also worked for six months as a visiting research scholar at Istituto Superiore di Sanità, Rome, Italy where he performed experiments to identify microRNA biomarkers associated with hepatoblastoma. While at the National Cancer Institute, Kaler studied interactions between the guanine nucleotide exchange factor Vav and protein kinase C isoforms in the Laboratory of Cancer Biology and Genetics headed by Peter M. He also worked for two summers as a research student in the National Cancer Institute of NIH. BAP1 is a gene that provides instructions for making proteins that control cell growth and cell division.ĭuring his RPB fellowship, Kaler will explore functional link(s) between BAP1 loss and aberrant activity of the NuRD (nucleosome remodeling and deacetylase) complex, which normally mediates embryonic lineage commitment and cellular differentiation.Īccording to the news release, Kaler earned a bachelor’s degree in history, cum laude, from Boston College and completed the Postbaccalaureate Premedical Program at Columbia University.
Using biochemical, cellular, and genetic methods, Kaler focuses on the dual roles of BAP1 in a rare ocular cancer, class 2 uveal melanoma, and in normal eye development.
This laboratory takes a broad approach to research, looking at genetics and genomics, cell biology, computational biology, developmental biology and bioinformatics to elucidate new therapies for patients with eye cancer. He also has worked part-time in Bascom Palmer’s Ocular Oncology Laboratory since his freshman year of medical school. Kaler has received a Research to Prevent Blindness (RPB) Medical Student Eye Research Fellowship, enabling him to take a year off from medical school to devote his time to a research project at Bascom Palmer.Īccording to the university, Kaler is currently between his 3rd and 4th years of medical school in the combined MD/MPH program at the University of Miami Miller School of Medicine. Bascom Palmer Eye Institute of the University of Miami Miller School of Medicine announced this week that Christopher J.
0 kommentar(er)
